# A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD

> **NCT02140346** · PHASE1 · COMPLETED · sponsor: **Respivert Ltd** · enrollment: 48 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** RV1729 28 day repeat dose
- **DRUG:** RV1729 matching placebo 28 day repeat dose

## Key facts

- **NCT ID:** NCT02140346
- **Lead sponsor:** Respivert Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2015-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02140346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02140346, "A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02140346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*